spacer
home > > autumn 2003 > recruiting hiv infected patients for anti-retroviral clinical trials in cee and the russian federation
PUBLICATIONS


Recruiting HIV Infected Patients for Anti-Retroviral Clinical Trials in CEE and the Russian Federation

Over the past decade the number of international clinical trials performed in Central and Eastern Europe (CEE) has continuously increased. Amongst these countries, Poland has become a regular partner in the conduct of clinical trials although this is not yet the case for most other CEE countries. Since the start of the first trial in the Russian Federation only about 120 trials have been conducted there (1). However, given the positive aspects of performing clinical trials in CEE countries and the Russian Federation, one can expect the number of trials to increase over time. To explain, site staff tend to be very motivated and eager to participate in clinical trials, while the quality of work and ICH GCP compliance is largely impeccable. Even more important when conducting clinical trials, recruitment in CEE countries and the Russian Federation appears to be higher than in most Western European countries. This again is not only because of the motivated staff but also because of the availability of the potential trial population.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Stefan Comhaire, Project Manager at Medisearch International

Having begun his career in basic scientific research, Stefan Comhaire joined Medisearch International over five years ago. Starting in clinical research as a CRA, he is now a Project Manager in charge of setting up the collaboration with the CEE and the Russian Federation five years ago, during which he established long-lasting collaboration with Russian and Polish investigators. As a specialist in infectious diseases, he has led several clinical trials in HIV, most of them also recruiting in Eastern Europe and/or Russia.

spacer
Stefan Comhaire
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Annual General Meeting of Gerresheimer AG approves dividend increase to EUR 1.20 per share

Duesseldorf, June 24, 2020—Payment of a dividend of EUR 1.20 per share was approved at the virtual Annual General Meeting of Gerresheimer AG.
More info >>

White Papers

Investigator Portals: Facilitating and Streamlining Communication & Collaboration with Study Sites

ArisGlobal

ArisGlobal LLC Investigator site personnel are often frustrated with the lack of transparency and communication with their sponsors, leading to significant dissatisfaction and withdrawal from current and future studies. The adoption of investigator portals gives sponsors a platform that fosters collaboration and improves site management. Learn about five key areas of sponsor-investigator site interactions deserving of electronic communication and collaboration. Technology and design aspects are also covered.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement